{'fraction_non_alphanumeric': 0.026912181303116147, 'fraction_numerical': 0.026912181303116147, 'mean_word_length': 5.36936936936937, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Value-based payment models in oncology: will they help or hinder patient access to new treatments?

Introduction The costs of treating cancer are rising: approximately $124.6 billion in 2010 in the United States and projected to grow to between $158 billion and $173 billion by 2020.1 This increased spending on cancer care can be attributed to a number of factors, including an aging population, growth in the number of individuals with insurance coverage, earlier diagnoses, and longer survival rates. We have also made advances in surgeries, radiation therapies, and medications—such as advanced immunotherapies and targeted therapeutics. But these advancements run parallel with rising treatment costs.